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Methodology
Researchers from the Horizons Program and the 
International Centre for Reproductive Health, 
in collaboration with Coast Province General 
Hospital, Mkomani Bomu Clinic, and Port Reitz 
District Hospital, conducted a randomized, con-
trolled, two-arm study to determine the short-term 
and longer-term effects of DAART compared to 
standard of care. Ethical approval for the study 
was obtained from the Ethical Review Board at 
Kenyatta National Hospital and the Institutional 
















Promoting Adherence through A 
directly Administered AntiretrovirAl 
therAPy strAtegy in mombAsA, KenyA
To read more about this study, go to 
www.popcouncil.org/horizons/projects/Kenya_HAARTMombasa.htm
A directly-administered 
antiretroviral therapy strategy 
(DAART) was more effective in 
promoting adherence during 
the 24-week intervention period 
than standard of care, but the 
effect was not sustained post-
intervention. DAART patients 
had greater improvements in 
body mass index and depression 
scores than non-DAART 
patients. Results suggest that 
DAART is effective for improving 
adherence in this setting, but the 
optimal length of the intervention 
for sustaining adherence and its 
transition to standard care may 
warrant further research. 
A  principal concern of antiretroviral therapy  (ART) programs is the ability of clients to maintain a high level of adherence to med-
ication. Based on formative research conducted 
with HIV-infected clients and health workers in 
Mombasa, Kenya, and lessons learned from direct-
ly observed therapy (DOT) strategies to encourage 
adherence to treatment for tuberculosis, a DAART 
strategy to promote adherence to ART was devel-
oped. This study examined whether the DAART 
intervention was more effective in fostering ad-
herence to ART than standard follow up among 









Jerry Okal (left), a key research assistant, with a community 
health worker who counsels ART patients on adherence.
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A total of 234 HIV-infected, treatment 
naïve patients who initiated highly ac-
tive antiretroviral therapy (HAART) 
were enrolled in the study between 
September 2003 and November 2004 
and were randomized to either the 
DAART arm or the standard of care 
arm. All patients received a first line  
non-nucleoside reverse transcriptase 
inhibitor (NNRTI) containing treat-
ment regimen (stavudine, lamivudine 
and efavirenz or nevirapine) and were 
followed for 72 weeks. All patients 
received standard adherence counseling consisting of 
3 one-on-one preparatory sessions prior to initiating 
HAART as well as ongoing needs-based counseling 
support at routine monthly clinic visits. 
The DAART intervention lasted for a period of 24 
weeks. During this time, participants in the DAART 
arm visited a health center twice a week where they 
met with DAART observers (nurses) who observed 
the ingestion of one dose of antiretroviral medica-
tions, performed pill-counts, collected used medica-
tion bottles, enquired about difficulties encountered, 
and provided individualized adherence support. At 
these visits medications were dispensed for the fol-
lowing three or four days, until the next visit. To 
enhance convenience, participants could select one 
of six health centers for their DAART visits. During 
the DAART intervention, community health work-
ers (CHWs) traced participants who missed visits and 
carried medications home for those who, for reasons 
of ill-health, were unable to visit the center. After the 
first 24 weeks, DAART patients were followed by rou-
tine monthly visits for a further 48 weeks. 
Non-DAART patients received standard monthly fol-
low up for the entire 72 weeks. This involved adher-
ence counselling and routine monthly follow-up clinic 
visits. CHWs traced DAART and non-DAART cli-
ents who did not keep the routine monthly follow-up 
clinic appointments. 
Adherence was assessed using clinic-based pill counts 
that measured adherence over a four-week period. 
Pill counts were undertaken every four weeks for 48 
weeks of follow up and again at 72 weeks. Adherence 
was calculated by dividing the number of pills actually 
taken by the number of pills the client 
was required to take over the report-
ing period multiplied by 100. Adher-
ence was dichotomized to ≥ 95 per-
cent and < 95 percent. The primary 
indicator for adherence in this study 
was the proportion of patients able to 
achieve ≥ 95 percent adherence over 
0–24, 25–48 and at 72 weeks. A p 
value of < 0.05 was considered signifi-
cant. Self-reported adherence based 
on a 4-day recall of missed doses was 
also used to assess adherence.
Patients who did not complete at least 30 days in the 
study were excluded from the analysis. Participants 
known not to have collected medication from the 
pharmacy, or who had dropped out of the study were 
awarded < 95 percent adherence for that reporting pe-
riod and thereafter treated as missing data. Those who 
attended clinic visits but failed to bring back bottles 
were considered missing pill counts for that report-
ing period. Some came back with fewer pills than 
expected, possibly due to misplaced pills, repeated 
ingestion if pills had been vomited, or pill dumping. 
Fewer pills than expected produce values of adherence 
greater than 100 percent; in these instances patients 
were given an adherence value equal to 100 minus the 
excess percent adherence (e.g., 102 percent adherence 
was given 98 percent). Patients who died were consid-
ered to have < 95 percent adherence for the reporting 
period immediately following their death and thereaf-
ter treated as missing.
A secondary outcome indicator for the study was the 
proportion of patients with undetectable virus (< 400 
copies/ml) at 48 and 72 weeks. High levels of adher-
ence allow patients to achieve maximum treatment ef-
fectiveness and undetectable virus in the blood. Thus 
viral load is a proxy marker for adherence. Viral load 
testing was conducted at 48 weeks and 72 weeks.
Other health outcomes assessed in the study included 
CD4 cell counts, body weight, and depression. CD4 
counts, a measure of immunological function, and 
body weight are expected to rise with ART. Body 
mass index (weight in kg/height in m2) is a reliable 
indicator for body fat and nutritional status. To assess 
depression among study participants, the research-
Horizons conducts global operations 
research to improve HIV/AIDS 
prevention, care, and support 
programs. Horizons is implemented by 
the Population Council in partnership 
with the International Center for 
Research on Women (ICRW), PATH, 
the International HIV/AIDS Alliance, 
Tulane University, Family Health 
International, and Johns Hopkins 
University. 
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the non-DAART arm completed 72 weeks of follow 
up. Twenty-five patients died before completing 72 
weeks of follow up (DAART: 14; non-DAART: 10); 
the majority of these died in the first 24 weeks of fol-
low up (67 percent). Ten patients discontinued the 
intervention: six patients transferred to other hospitals 
(DAART: 2; non-DAART: 4) and four non-DAART 
patients stopped treatment. Ten patients were lost to 
follow up, their whereabouts unknown (DAART: 6; 
non-DAART: 4).
Sociodemographic characteristics were similar across 
the two groups (Table 1). Almost two- thirds (64 
percent) of patients were female, half of them had 
received primary education, and half were currently 
married. The median age was 36 years (IQR: 31–43). 
The median CD4 cell counts were 99 cells/mm3 (IQR 
49–145) at baseline; nearly a quarter of the patients 
had CD4 cell counts less than 50 cells/mm3 at the be-
ginning of the study. 
There were no significant differences with regard to 
age, sex, and CD4 counts between patients lost to 
follow up and patients completing the study. During 
the study one patient changed to a protease inhibitor-
based treatment regimen (AZT, DDI, Lopinavir/
Ritonavir). 
Key Findings 
The majority of patients made 90 percent or 
more of expected DAART visits.
The DAART intervention required patients to 
make a total of 48 visits over 24 weeks of follow 
up to DAART observation sites to pick up their 
medication and be observed taking a dose. Ar-
rangements were made to provide medications to 
patients who wanted to travel outside of Mombasa.
Service data from DAART sites show that 59  
percent of DAART patients who completed 24 
weeks of follow up (n = 94) attended 90 percent 
or more of DAART visits, 16 percent attended 
between 80 to 89 percent of required visits, and 
20 percent attended between 50 to 79 percent of 
visits. Only 4 percent attended less than half of re-
quired visits.
ers used the Beck Depression Inventory I®, a 21-item 
validated tool. The tool was culturally adapted to the 
Kenyan context before application. Changes in CD4 
cell counts, body mass index (BMI), and depression 
scores were calculated for each patient with baseline 
and secondary measurements and the median change 
for each indicator was calculated for the group.
This summary presents the results from 72 weeks of 
follow up. The findings focus on adherence during 
the DAART intervention period (0–24 weeks) and 
on sustained adherence in the early post-intervention 
period (25–48 weeks) and on longer-term adherence 
after the intervention (72 weeks).
Recruitment and Retention
A total of 234 patients were recruited; 116 patients 
were randomized to the DAART arm and 118 to the 
non-DAART arm. Seven patients did not receive the 
allocated intervention due to death prior to starting 
ART (n = 3), withdrawal (n = 3), and severe illness 
(n = 1). Thus 227 patients were eligible for adher-
ence monitoring (DAART: 111; non-DAART: 116). 
Eighty-nine patients in the DAART arm and 94 in 
A team of community health workers who trace 
clients who do not appear for observed treatment or 









The DAART group had higher adherence 
during the intervention period however, the 
effect was not sustained post-intervention. 
Data from pill counts show that a significantly higher 
proportion of patients in the DAART group were able 
to achieve adherence ≥ 95 percent during the inter-
vention period (0–24 weeks; p = 0.012) compared to 
patients in the control group (Figure 1). However the 
effect was not sustained and the difference between 
groups was not statistically significant both in the 
early post intervention period (25–48 weeks) and in 
the late post-intervention period (72 weeks). Adher-
ence declined sharply in the DAART group in the 
early post intervention period when DAART supervi-
sion was withdrawn. 
A similar trend was obtained with self reported ad-
herence using a 4-day recall. A significantly smaller 
proportion of DAART patients reported missed doses 
during 0–24 weeks compared to the non-DAART pa-
tients (9 percent vs. 19 percent; p = 0.04). There were 
no significant differences in the post intervention pe-
riod (25–48 wks: 13 percent vs. 13 percent; p = 0.92; 
72 wks: 3 percent vs. 5 percent; p = 0.49)
Viral load suppression was not significantly 
greater among DAART patients. 
More patients in the DAART arm achieved viral loads 
< 400 copies/ml at 48 weeks compared to those in 
the control group, but the difference was not statisti-
cally significant (88 percent vs. 78 percent). At 72 
weeks, the figures for the two groups were similar (74 
percent vs. 77 percent), but this was due to a decline 
in the number of patients in the DAART group who 
achieved undetectable viral loads (88 percent to 74 
percent). 
 
Both groups demonstrated immunological 
improvement.
At baseline, there were no significant differences in 
median CD4 counts between groups. Patients in both 
groups with baseline and secondary measurements 
demonstrated improvements in median CD4 counts 
at 24, 48, and 72 weeks. But there was no significant 
difference in the median change in CD4 counts be-
tween the two groups over 0–24 weeks, 0–48 weeks, 
and 0–72 weeks (Figure 2). 































those in the control group, the difference was not sta-
tistically significant (Figure 3).
 
Patients in the DAART group had greater 
improvement in depression scores
At the beginning of the study, nearly a third of the 
patients in both groups reported moderate to severe 
depression (31.7 percent). There were no differ-
ences in depression scores between groups at baseline 
(DAART: 15.6 vs. non-DAART: 14.5; p = 0.23). 
DAART patients had greater improvements in 
body mass index. 
There was no difference in BMI scores between the 
two groups at baseline (DAART: 20.6 kg/m2 vs. non-
DAART: 20.8 kg/m2). Significant improvements in 
BMI were observed in both groups. Patients in the 
DAART group had a significantly greater mean in-
crease in BMI over 0–24 (p = 0.014) and 25–48 (p = 
0.047) weeks compared to those in the control group. 
Although patients in the DAART group had a higher 
mean increase in BMI at 0–72 weeks compared to 
Figure 2   Baseline CD4 counts and median increase in CD4 counts in the study groups over 24, 48 and
  72 weeks of follow up



























































Both groups demonstrated significant reductions in 
depression scores over 72 weeks on treatment. The 
DAART group had a significantly larger median de-
crease in depression scores at 0–48 weeks (p = 0.04) 
and 0–72 (p = 0.03) weeks, but not at 0–24 weeks 
(Figure 4). 
DAART was particularly effective in 
promoting adherence among depressed 
patients.
During the intervention phase (0–24 weeks), patients 
with moderate to severe depression in the DAART 
arm were seven times as likely to achieve ≥ 95 percent 
adherence than comparably depressed patients in the 
control arm (OR = 7.0; 95% CI: 2.7–18.0; p < 0.001) 
[Data not shown]. But after week 24, there was no 
longer any difference in adherence levels among mod-
erately to severely depressed patients by study arm. 
Conclusions
High levels of adherence to HAART were observed 
for all patients during the first 24 weeks. DAART was 
more effective in promoting adherence during the in-
tervention period (0–24 weeks); a higher proportion 
of patients in the DAART group achieved ≥ 95 per-
cent adherence during the intervention period com-
pared to those in the non-DAART group. DAART 
patients also had greater increases in BMI during 
the intervention period and from 0 to 48 weeks, and 
larger declines in depression scores at 0–48 weeks and 
0–72 weeks. 
Study findings suggest that DAART may be particu-
larly useful among patients with moderate to severe 
depression, which is common among HIV-infected 
persons (Ciesla and Roberts 2001). Depression has 
previously been shown to be an independent predictor 
of poor adherence (Paterson et al. 2000; Gordillo et 
al. 1999). Further, both non-adherence and depressive 
symptoms are associated with higher mortality among 
patients receiving ART (Lima et al. 2007). Though 
this finding needs to be confirmed, it suggests that 
DAART may be particularly useful for this high-risk 
subgroup.
However, the effects of the intervention on adherence 
were not sustained in the early and late post-interven-
tion periods. Moreover, adherence declined over time 
in both groups, which is of concern to ART programs. 
The decline was sharper in the DAART group in the 
period following the cessation of the intervention, 
possibly due to the sudden withdrawal of adherence 
support. A gradual stepping down to standard care 
may have prevented this decline and needs to be con-
sidered by all programs using a modified DOT ap-
proach to promote adherence.
Figure 4   Median decrease in depresssion scores in the study groups over 24, 48 and 


































It is of note that a quarter of the patients in both 
groups had detectable virus at 72 weeks indicating 
treatment failure, despite the fact that all patients were 
ART naïve and received first line NNRTI treatment 
regimens. This is of concern given that recent research 
suggests that patients receiving NNRTI treatment reg-
imens may be able to achieve undetectable viral loads 
even with adherence levels lower than ≥ 95 percent 
(Maggiolo et al. 2005; Weiser et al. 2004). 
In conclusion, the DAART intervention was success-
ful in promoting adherence during the intervention 
A larger proportion of patients in the DAART group 
compared to the control group achieved undetectable 
viral loads at 48 weeks, although the difference be-
tween groups was not statistically significant. Higher 
adherence during the intervention period as a result 
of DAART may have had a beneficial effect extending 
beyond the intervention period. The larger decline 
over time in the proportion of patients achieving viral 
load suppression in the DAART group, compared to 
the control group, may have occurred as a result of 
lower adherence in the wake of the cessation of the 
DAART intervention. 
Estimated Incremental Annual Cost Per Patient of a Directly  
Administered Antiretroviral Therapy Program
The incremental annual cost of a DAART program was determined by the value of the additional 
resources required to support the program. In the Mombasa program the additional resources re-
quired include: staff time at the health facility to observe the clients, staff time of the CHWs who 
served as trackers, and additional transportation and communication expenses for the trackers. The 
volume of additional resources required was estimated as part of a larger costing study of the ART 
program at Coast Province General Hospital (CPGH) conducted in 2004–05, which measured ex-
penses from the previous year (2003–04).
Additional staff time at the health facility was estimated through a patient flow analysis of the com-
prehensive care center at CPGH. Contacts with health facility staff by DAART clients were com-
pared to non-DAART clients to estimate the additional staff time required to support the DAART 
program. This additional staff time was then converted to a cost estimate based upon standard Min-
istry of Health payment rates for the different job categories at CPGH. 
Program records of monthly payments made to the CHWs to serve as trackers (1,000 Ksh per 
tracker per month) as well as the additional transportation and communication payments to trackers 
were used to estimate the incremental cost of the DAART program associated with the use of track-
ers.
Combining the value of the additional staff time at the health facility with the payments made to the 
trackers yielded the incremental cost of the DAART program. All costs were then inflated to an an-
nual period and divided by the number of clients served in the project to yield the estimated annual 
cost per client for the DAART program.
 
Results
For the DAART program in Mombasa, Kenya, the annual incremental cost per client was 2,164 KSh 
per client (~USD31). The value of the additional health facility staff time accounted for 80 percent of 
the total cost while the payments to the CHWs for their tracking activities accounted for the remain-
ing 20 percent (USD6.20). In terms of additional expenditures, only the payments to the CHWs for 
their efforts and their transportation and communication expenses represented additional monetary 
costs to the program. 
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period but not after the intervention ended. Overall 
results suggest that DAART is effective within certain 
parameters, but the optimum duration of the inter-
vention is unclear and ways to sustain the effects of 
the intervention warrant more research. 
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